DUBLIN–(BUSINESS WIRE)–The “Bispecific Antibodies Market (5th Edition) 2023-2035” report has been added to ResearchAndMarkets.com’s offering.
This report features an extensive study of the current market landscape and future opportunity for the players involved in the development and manufacturing of bispecific therapeutic antibodies for treating various oncological and non-oncological disorders. The report answers many key questions related to this domain.
Bispecific Antibody Therapeutics Market Overview
Bispecific antibodies (BsAbs) represent a novel class of antibodies that act by simultaneously attaching to two separate / distinct antigens or different epitopes of the same antigen.
These drugs primarily function by redirecting immune effector cells to effectively eliminate cancer cells using various mechanisms, such as antibody-dependent cell mediated cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC).
Further, bispecific antibody drugs possess unique biological and pharmacological characteristics and are available in a wide range of formats, making them a promising option for therapeutic use. It is worth mentioning that, till date, nine bispecific antibodies have been approved for therapeutic use; these are (arranged in reverse chronological order of their initial approval) TecvayliT (October 2022), Nanozora (September 2022), AK104 (June 2022), Lunsumio (June 2022), VABYSMOT (February 2022), KIMMTRAK (January 2022), RYBREVANTT (May 2021), Hemlibra (November 2017) and Blincyto (December 2014).
Additionally, in the last few years, a definite surge in clinical trials being conducted to evaluate bispecific antibodies has been observed, given the rising popularity and potential therapeutic benefits of such candidates. In the foreseen future, as more such therapeutic candidates move into the clinical stage and / or receive approval, we anticipate the bispecific antibody therapeutics market to witness healthy growth.
Rising Interest in Bispecific Antibody Therapeutics
The growing pipeline of bispecific antibodies and the increasing number of associated clinical trials to evaluate the effectiveness of such candidates indicate a high level of interest and investment in this field.
Pipeline Analysis of Bispecific Antibodies
Bispecific antibody landscape features the presence of over 120 large, mid-sized and small drug developers. It is worth mentioning that, currently, over 220 bispecific antibodies are either approved or being evaluated in clinical stages of development, whereas over 180 candidates are in preclinical stages of development. In addition, we came across various contract manufacturing / research organizations that are engaged in this domain.
Bispecific Antibodies are Mainly Targeting Cancer
The increasing prevalence of chronic diseases, such as oncological disorders, autoimmune disorders and infectious diseases, is expected to drive the market for bispecific antibody therapeutics. Such therapeutics offer a promising approach by targeting multiple disease pathways, simultaneously. Currently, there are more than 15 bispecific antibodies in development for the treatment of gastric cancer.
In March 2023, Akeso Biopharma announced the completion of enrollment for a phase III trial for Cadonilimab for use in combination with chemotherapy as first-line therapy for advanced gastric or gastroesophageal junction cancer. It is also worth highlighting that the most recent approval of TecvayliT for relapsed or refractory multiple myeloma has expanded the target indications where bispecific antibodies have proven their efficacy.
Market Size of the Bispecific Antibodies Market
Driven by the rising interest in R&D activities and growing demand for effective therapeutics, the bispecific antibody therapeutics market is anticipated to witness an annualized growth rate of over 9.5%, during the period 2023-2035.
Specifically, in terms of therapeutic areas, the market is anticipated to be driven by drugs targeting oncology disorders. In addition, presently, close to 64% of the market is captured by players based in North America and Europe.
Key Players in the Bispecific Antibodies Market
Examples of key players engaged in this domain (which have also been captured in this report, arranged in alphabetical order) include Akeso Biopharma, Amgen, Astrazeneca, Genmab, Immunocore, Janssen Research & Development, Merck, Roche and Zymeworks. Roche is playing a key role in taking the bispecific antibodies from development to commercialization, with three approvals to date.
Two of these approvals came in 2022 – VabysmoT in February 2022 and TecvayliT in October 2022. Another of Roche’s bispecific antibody, Glofitamab, received priority review from FDA for the treatment of relapsed or refractory large b-cell lymphoma and is likely to receive approval soon.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE OF APPROVED AND CLINICAL THERAPIES
5. MARKET LANDSCAPE OF PRECLINICAL THERAPIES
6. KEY INSIGHTS
7. TECHNOLOGY ASSESSMENT FRAMEWORK
8. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS
9. COMPANY PROFILES
10. PARTNERSHIPS AND COLLABORATIONS
11. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS
12. CLINICAL TRIAL ANALYSIS
13. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES
14. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
16. SWOT ANALYSIS
17. CONCLUDING REMARKS
18. EXECUTIVE INSIGHTS
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
For more information about this report visit https://www.researchandmarkets.com/r/ojpimm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900